Aspire BioPharma is trading 5.9% down at $7.16, with no clear company-specific catalyst identified for the August 12, 2026 decline.

  • On August 10, the company completed the approximately $30 million acquisition of Dura Driver Control Systems.
  • The acquisition was funded partly through a $22.5 million revolving credit facility.
  • Broader markets were higher, so market-wide weakness does not clearly explain the move.